Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

Mild cognitive impairment… - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

Kontaktformulär








 


OBS! Vill du ha svar, ange e-post eller telefonnummer!




Mild cognitive impairment with suspected nonamyloid pathology (SNAP) Prediction of progression

Artikel i vetenskaplig tidskrift
Författare A. Caroli
A. Prestia
S. Galluzzi
C. Ferrari
W. M. van der Flier
R. Ossenkoppele
B. Van Berckel
F. Barkhof
C. Teunissen
A. E. Wall
S. F. Carter
Michael Schöll
I. H. Choo
T. Grimmer
A. Redolfi
A. Nordberg
P. Scheltens
A. Drzezga
G. B. Frisoni
Publicerad i Neurology
Volym 84
Nummer/häfte 5
Sidor 508-515
ISSN 0028-3878
Publiceringsår 2015
Publicerad vid Institutionen för neurovetenskap och fysiologi, sektionen för klinisk neurovetenskap och rehabilitering
Sidor 508-515
Språk en
Länkar dx.doi.org/10.1212/wnl.000000000000...
Ämnesord CEREBROSPINAL-FLUID BIOMARKERS, ALZHEIMERS-DISEASE, NATIONAL INSTITUTE, BETA, DEMENTIA, AD, RECOMMENDATIONS, ACCURACY, MARKERS, TANGLE, Clinical Neurology
Ämneskategorier Neurovetenskaper

Sammanfattning

Objectives:The aim of this study was to investigate predictors of progressive cognitive deterioration in patients with suspected non-Alzheimer disease pathology (SNAP) and mild cognitive impairment (MCI).Methods:We measured markers of amyloid pathology (CSF -amyloid 42) and neurodegeneration (hippocampal volume on MRI and cortical metabolism on [F-18]-fluorodeoxyglucose-PET) in 201 patients with MCI clinically followed for up to 6 years to detect progressive cognitive deterioration. We categorized patients with MCI as A+/A- and N+/N- based on presence/absence of amyloid pathology and neurodegeneration. SNAPs were A-N+ cases.Results:The proportion of progressors was 11% (8/41), 34% (14/41), 56% (19/34), and 71% (60/85) in A-N-, A+N-, SNAP, and A+N+, respectively; the proportion of APOE epsilon 4 carriers was 29%, 70%, 31%, and 71%, respectively, with the SNAP group featuring a significantly different proportion than both A+N- and A+N+ groups (p 0.005). Hypometabolism in SNAP patients was comparable to A+N+ patients (p = 0.154), while hippocampal atrophy was more severe in SNAP patients (p = 0.002). Compared with A-N-, SNAP and A+N+ patients had significant risk of progressive cognitive deterioration (hazard ratio = 2.7 and 3.8, p = 0.016 and p < 0.001), while A+N- patients did not (hazard ratio = 1.13, p = 0.771). In A+N- and A+N+ groups, none of the biomarkers predicted time to progression. In the SNAP group, lower time to progression was correlated with greater hypometabolism (r = 0.42, p = 0.073).Conclusions:Our findings support the notion that patients with SNAP MCI feature a specific risk progression profile.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?